3 high-quality ASX shares to buy while they are cheap

Smiling couple looking at a phone at a bargain opportunity.

While markets continue to swing on headlines and macro uncertainty, experienced investors are often doing something very different behind the scenes. They are focusing on quality.

Not just companies with strong recent performance, but businesses with durable advantages, long growth runways, and the ability to keep compounding over time.

Here are three ASX shares that fit that description and could be worth a closer look following recent share price weakness.

Cochlear Ltd (ASX: COH)

The first ASX share that stands out is Cochlear. It is a medical device company that operates a highly specialised global ecosystem built around hearing implants.

What makes it a quality business is not just its technology leadership, but the longevity of its customer relationships. Once a patient enters the system, they often remain within it for decades through upgrades, servicing, and support.

This creates a steady and growing revenue base that is less dependent on constant new customer acquisition.

With hearing loss becoming more prevalent globally and access to treatment still expanding, Cochlear has a long runway ahead. For investors focused on quality, that combination of recurring revenue and structural demand is hard to ignore.

Life360 Inc (ASX: 360)

Another ASX share that could appeal to quality-focused investors is Life360.

This family safety technology company has been growing at a rapid rate for many years and has around 100 million monthly active users (MAUs) now.

From these users, the company is generating significant subscription revenues and a growing stream of advertising income.

And with management confident that its strong growth can continue in 2026, the future is looking bright for this one. This is especially the case given its plans to expand its offering into pet tracking and other areas.

The company is essentially building a product that integrates into everyday life. And that kind of engagement can be a powerful foundation for long-term value creation.

Pro Medicus Ltd (ASX: PME)

A third ASX share that fits firmly in the quality category is Pro Medicus.

Pro Medicus operates in medical imaging software, but what sets it apart is its business model.

The company focuses on winning large, long-term contracts with leading hospitals and healthcare providers. Once embedded, its solutions become critical to operations, creating high switching costs and strong customer retention.

What is particularly compelling is its ability to scale without a corresponding increase in costs. This has led to exceptional margins and strong cash generation.

Despite already delivering significant growth, Pro Medicus continues to win new contracts globally, particularly in the United States.

And with its shares down heavily from their highs, now could be an opportune time to invest for the long term.

The post 3 high-quality ASX shares to buy while they are cheap appeared first on The Motley Fool Australia.

Should you invest $1,000 in Life360 right now?

Before you buy Life360 shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Life360 wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys…

* Returns as of 20 Feb 2026

.custom-cta-button p {
margin-bottom: 0 !important;
}

More reading

Motley Fool contributor James Mickleboro has positions in Cochlear, Life360, and Pro Medicus. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear and Life360. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Life360. The Motley Fool Australia has recommended Cochlear and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.